New advances in the treatment of advanced lung cancer
The University of Barcelona (UB) and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic and antifibrotic drug, for the treatment of lung cancer. This public-private collaboration enabled researchers identify molecular mechanisms underlying the lack of efficiency of this drug in squamous cell carcinoma, a sub-type of non-small cell lung cancer, and the important role of smoking in this lack of effectivity.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Hospitals | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals | Skin Cancer | Smokers | Squamous Cell Carcinoma